The thesis

ONC is a biotech company with a commercial-stage product, BRUKINSA, showing 29.6% YoY revenue growth. The conviction score is 27/100, indicating medium conviction. Despite a high P/E of 81.4x, the company's gross margin is 8782.0%, suggesting strong profitability. Analyst consensus is BUY, but the DCF intrinsic value is negative, indicating potential valuation risk.

Why now

The current market volatility, with the S&P 500 and Nasdaq slipping due to inflation fears, makes ONC's strong revenue growth and high margins more notable. The 29.6% YoY revenue growth is a catalyst that makes this the right moment to pay attention.

What to watch

ONC's next quarterly revenue growth report will be crucial in confirming or denying the thesis. Investors should also watch for any updates on BRUKINSA sales and the company's pipeline progress over the next 1-3 quarters.

Key risks

The high P/E ratio of 81.4x poses a valuation risk if revenue growth slows. Execution risk is also present, as the company's negative DCF intrinsic value could indicate overvaluation. Macro risk from inflation fears and market volatility could impact investor sentiment.

Theme exposure